3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
3
Status
Completed
9
Terminated
3
Active not recruiting
3
Recruiting
2
Withdrawn
1
Unknown
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Conditions
Prostatic Neoplasms
26
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma
14
Burkitt Lymphoma
10
Neoplasms
8
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Lymphoma, Follicular
7
Lymphoma, B-Cell
7
Hodgkin Disease
6
Lymphoma, Non-Hodgkin
4
Recurrence
3
Prostatic Neoplasms, Castration-Resistant
3
Leukemia
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Multiple Myeloma
2
Melanoma
2
Lymphoproliferative Disorders
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, AIDS-Related
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia, Biphenotypic, Acute
2
Immunoblastic Lymphadenopathy
2
Vasculitis, Central Nervous System
1
Urogenital Neoplasms
1
Stiff-Person Syndrome
1
Stage II Prostate Adenocarcinoma
1
Skin Neoplasms
1
Rasmussen subacute encephalitis
1
Prostate Cancer, Hereditary, 7
1
Interventions
Dexamethasone
18
Cyclophosphamide
16
fludarabine
11
pomalidomide
9
pembrolizumab
9
carfilzomib
9
daratumumab
7
Rituximab
7
Lenalidomide
7
Calcium Dobesilate
7
fludarabine phosphate
6
Cisplatin
6
Bortezomib
6
Gemcitabine
5
venetoclax
4
elotuzumab
4
isatuximab
3
Vincristine
3
Radiotherapy
3
Prednisone
3
Letrozole
3
Etoposide
3
Doxorubicin
3
Cytarabine
3
tisagenlecleucel
2
selinexor
2
ruxolitinib
2
palbociclib
2
ixazomib
2
dexamethasone 21-phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Recurrence
×
Prednisone
×
Clear all
NCT05888493
2026-04-17
LEDA
Novartis
Phase 3
Active not recruiting
109 enrolled
NCT06097364
2026-02-06
OLYMPIA-2
Regeneron Pharmaceuticals
Phase 3
Active not recruiting
733 enrolled
NCT05578976
2025-01-23
EPCORE DLBCL-2
Genmab
Phase 3
Active not recruiting
900 enrolled